Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

Trial Profile

An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2018

At a glance

  • Drugs APL 2 (Primary)
  • Indications Autoimmune haemolytic anaemia
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
  • Acronyms PLAUDIT
  • Sponsors Apellis Pharmaceuticals
  • Most Recent Events

    • 03 Dec 2018 According to an Apellis media release, Dr. Morie A. Gertz, M.D. (MACP, Chair Emeritus Department of Medicine of the Department of Hematology at the Mayo Clinic in Rochester, Minnesota) is the principal investigator of this study.
    • 01 Nov 2018 According to an Apellis media release, this trial has been accepted for poster presentations at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition, and the abstract was published on the ASH conference website.
    • 05 Oct 2018 Planned number of patients changed from 12 to 24.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top